Bioasis Tech Stock Price, News & Analysis

BIOASIS TECHNOLOGIES INC (BIOAF) is a multi-asset rare and orphan disease biopharmaceutical company focused on developing clinical stage programs utilizing epidermal growth factor and the xB3 ™ platform. They specialize in delivering therapeutics across the blood-brain barrier for the treatment of CNS disorders with high unmet medical needs. Despite facing financial challenges due to a failed merger, Bioasis is exploring strategic alternatives to enhance shareholder value. The company recently signed a non-binding term sheet with Swiss Biotech Advisors for an exclusive worldwide license of the EGF Assets, which could potentially generate revenue in the future. However, due to limited cash resources, the company has decided to suspend all operations. Bioasis aims to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.